Prostate Cancer Hypofractionation
Prostate cancer is the most common malignancy diagnosed in men in the USA, and in 2016 it is estimated that over 180,000 men will be diagnosed with prostate cancer. Treatment options for prostate cancer are based on risk stratification with Gleason score, clinical stage, and PSA. Of interest to the radiation oncologist, prostate cancer is hypothesized to have an alpha/beta ratio of <2 offering a potential therapeutic benefit for hypofractionation. In addition to biological reasons, the frequency of prostate cancer and the high health-care cost of treatment have led to significant interest in shortening radiation treatment time. Recently several large randomized trials of hypofractionation have been published providing high quality level I evidence for the safety and efficacy of modest hypofractionation. There has been a more recent interest in SBRT for prostate cancer with many single and multiinstitutional studies reporting safety and efficacy.
KeywordsProstate cancer Hypofractionation Stereotactic body radiotherapy External beam radiation
- 5.Incrocci L, Wortel RC, Alemayehu WG, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016;17(8):1061–9.CrossRefPubMedGoogle Scholar
- 6.Lukka H. RTOG 0938 protocol information minimize: a randomized phase II trial of hypofractionated radiotherapy for favorable risk prostate cancer—RTOG CCOP Study. 2016. https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0938. Accessed 19 June 2017.
- 10.National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer Version 2.2017. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 6 Nov 2016.
- 13.Wilkins A, Mossop H, Syndikus I, et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. Dec 2015;16(16):1605–16.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Catton CN, Lukka H, Julian JA, et al. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. Paper presented at American Society of Clinical Oncology 2016; Chicago, IL.Google Scholar